Max Rossetto – Head of Business Development
Phone #: (07) 3273 9192
For Immediate Release
1 October 2021
Enterobiome chooses Luina Bio to for their early phase clinical trials
Partnership Extends Luina Bio’s Influence in Korea.
- Luina Bio will support Enterobiome in the process development and GMP manufacture of a promising Live Biotherapeutic candidate for a metabolic disease
- Enterobiome’s mission is to develop Live Biotherapeutics selected from the human gut microbiome.
- Luina Bio has been successful in scaling up manufacture of A.muciniphila strain through technology transfer of Enterobiome Inc.
Brisbane, Queensland – Luina Bio, one of Australia’s most experienced biopharmaceutical contract development and manufacturing (CDMO) organisations, is pleased to announce a new manufacturing project for a live biotherapeutic product (LBP) with Korean company, Enterobiome. With over 20 years’ experience in the pharmaceutical and biotechnology industries, Luina Bio focuses on each client’s specific needs and goals to solve some of the world’s biggest health problems.
“Luina Bio is proud to partner and provide manufacturing services to a range of companies all tackling therapeutics from human microbiota,” says Luina Bio Head of Business Development, Max Rossetto.
Enterobiome, a bio-venture company in Korea, has confirmed Luina Bio is their partner of choice for the manufacture of a live biotherapeutic product (LBP). Luina Bio will support Enterobiome in the process development and GMP manufacture of an Akkermansia muciniphila strain for early phase clinical trials in the area of metabolic disease. The work includes the technology transfer, development of fermentation and processing conditions to a larger scale.
Over the last decade, vast amounts of scientific discoveries have been made in the field of the human microbiota, leading to a deep appreciation of how closely the human microbiota is related to human health. A.muciniphila is gaining much attention due to the research links of probiotic potential in a certain diseased state.
“Enterobiome needed Luina Bio to support us in the next stage of scale up and we look forward to a long term commercial partnership,” says Enterobiome Chief Financial Officer Jinyoung Chang.
About Luina Bio
Luina Bio is one of Australia’s most experienced biopharmaceutical contract manufacturing organisations, offering an inclusive set of services including cGMP manufacture in TGA/APVMA-licensed facilities of recombinant proteins, vaccines, and synthetic molecules for human and veterinary uses. For more information, please visit www.luinabio.com.au.
Enterobiome is a bio-venture company in Korea, established in May 2018 by Dr. Jae-Gu Seo. The mission of the company is to develop pharmabiotics selected from the human gut microbiome. The promising pharmabiotic candidates are speculated to be more efficacious compared to the current probiotic products in the market as they have stronger scientific rationales to use. In this regard, Enterobiome hopes meet the need of the market and can contribute to improving ‘quality of human life’ through human microbiome technology. For more information, please visit http://enterobiome.com